Allogeneic "Zombie Cell" as Off-The-Shelf Vaccine for Postsurgical Cancer Immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Allogeneic tumor cell vaccines offer convenience but struggle with patient-specific tumor antigen heterogeneity.
• Existing vaccines lack the ability to address diverse tumor antigen profiles, limiting their efficacy.
• There is a need for adaptable vaccine platforms that can overcome tumor heterogeneity and immune evasion.

Purpose of the Study:

• To develop a novel allogeneic tumor cell vaccine platform, termed "zombie cells," capable of targeting heterogeneous tumor antigens.
• To evaluate the efficacy of "zombie cells" in consolidating tumor surgery and generating long-term antitumor immunity.
• To assess the potential of this platform as a generalizable strategy for post-operative cancer therapy.

Main Methods:

• Allogeneic tumor cell corpses were engineered into "zombie cells" with tumor assimilation and adjuvant spreading capabilities.
• Localized delivery of "zombie cells" via stepwise gelation in tumor resection cavities was performed in postoperative models.
• Immune responses, including T cell activation and immunological memory, were analyzed.
• Comparative studies were conducted against analogous vaccines lacking key "zombie cell" functionalities.

Main Results:

• "Zombie cells" demonstrated pseudo-oncolysis by assimilating heterogeneous tumor cells, enhancing phagocytosis and T cell responses.
• Localized delivery of "zombie cells" effectively consolidated tumor surgery and reduced residual tumor burden.
• The "zombie cell" platform induced robust, long-term antitumor immunity and immunological memory, comparable to autologous vaccines.
• This approach showed reduced susceptibility to immune evasion compared to control vaccines.

Conclusions:

• The "zombie cell" platform represents a versatile strategy for overcoming tumor heterogeneity and generating potent antitumor immunity.
• This off-the-shelf, yet personalized, vaccine approach shows significant promise for timely post-operative cancer therapy.
• The study suggests a viable alternative to conventional vaccines for enhancing long-term cancer patient outcomes.